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MECHANISMS OF DRUG-INDUCED LUPUS 
IV. Comparison of Procainamide and Hydralazine with Analogs In Vitro and In Vivo 
RAYMOND YUNG, SANDRA CHANG, NAHID HEMATI, KENT JOHNSON, and BRUCE RICHARDSON 
Objective. T cells treated with DNA methylation 
inhibitors overexpress lymphocyte function-associated 
antigen 1 (LFA-l), which results in autoreactivity, and 
the autoreactive cells cause a lupus-like disease in vivo, 
suggesting a mechanism by which some agents may 
cause drug-induced lupus. This study compared the 
effects of procainamide (Pca) and hydralazine (Hyd) 
with those of structural analogs, to determine if the 
degree of LFA-1 overexpression and T cell autoreactivity 
correlated with the ability of the agents to induce 
autoimmunity. 
Methods. Cloned murine T helper 2 cells were 
treated with Pca, N-acetylprocainamide, Hyd, Phthala- 
zine, or hydroxyurea (HU). The treated cells were then 
compared for LFA-1 overexpression, autoreactivity, and 
the ability to induce autoimmunity in vivo. 
Results. Pca and Hyd were more potent than their 
analogs or HU in all 3 assays. 
Conclusion. The results support a relationship 
between LFA-1 overexpression, T cell autoreactivity, 
and autoimmunity, and suggest a mechanism by which 
Pca and Hyd, but not the analogs, may cause drug- 
induced lupus. 
Procainamide (Pca) and hydralazine (Hyd) cause 
a lupus-like disease in some individuals, but the mecha- 
nism by which these drugs induce autoimmunity is 
uncertain. Understanding the mechanism is important, 
because similar mechanisms could contribute to the 
Supported by PHS grants 2-P60-AR-20557, F32-AI-08253, 
and R01-AR-42525, a Merit Review grant from the Veterans Admin- 
istration, and a grant from the Arthritis Foundation. 
Raymond Yung, MD, Sandra Chang, BS, Nahid Hemati, MS, 
Kent Johnson, MD, Bruce Richardson, MD, PhD: University of 
Michigan, Ann Arbor, and the Ann Arbor Veterans Administration 
Hospital, Ann Arbor, Michigan. 
Address reprint requests to Bruce Richardson, MD, PhD, 
R4540 Kresge 1, Ann Arbor, MI 48109-0531. 
Submitted for publication September 25, 1996; accepted in 
revised form March 21, 1997. 
development of idiopathic human lupus. Our group has 
reported that Pca and Hyd inhibit DNA methylation and 
induce autoreactivity in human T lymphocytes (1,2). We 
have also reported that inhibiting DNA methylation 
with Pca or 5-azacytidine (5-azaC), in cloned as well as 
polyclonal CD4-t murine T cells, causes a similar auto- 
reactivity, and that the CD4-t T cells made autoreactive 
by these drugs cause a lupus-like disease in nonirradi- 
ated syngeneic mice (3,4). The autoreactivity correlates 
with an increase in lymphocyte function-associated an- 
tigen 1 (LFA-1) expression (5 ) ,  and overexpression of 
LFA-1 by transfection causes a similar autoreactivity in 
vitro and autoimmune disease in vivo (6,7), demonstrat- 
ing that LFA-1 overexpression is important and proba- 
bly the major mechanism responsible for these effects. 
These results led us to hypothesize that some agents 
causing drug-induced lupus do so, in part, by interacting 
with T cells to induce LFA-1 overexpression, which 
results in autoreactivity, and the autoreactive cells then 
interact with immune cells in the host to produce the 
autoimmune disease (3,4). 
To further test the proposed relationship be- 
tween LFA-1 overexpression, T cell autoreactivity, and 
autoimmunity, we compared the effects of Pca and Hyd 
with those of structural analogs on murine T cell LFA-1 
expression and autoreactivity in vitro. We also compared 
cells treated with these drugs for their ability to induce 
autoimmunity in vivo. The effects of Pca were compared 
with those of N-acetylprocainamide (Napa), a metabo- 
lite which does not induce lupus (8,9). The effects of 
Hyd were compared with those of phthalazine (Phth), 
the parent molecule of Hyd, but lacking the hydrazine 
side chain. Phth has no clinical utility, so its ability to 
induce lupus is unknown. However, hydrazine com- 
pounds have been implicated in triggering some cases of 
lupus (lo), and the comparison of Hyd and Phth allows 
analysis of the role of hydrazine in this system. Finally, 
the effects of hydroxyurea (HU), a DNA synthesis 
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inhibitor ( l l ) ,  were also studied. In contrast to Pca and 
Hyd, HU increases D N A  methylation (12). 
The results showed that Pca and Hyd were more 
potent than their analogs and HU in increasing LFA-1 
expression, and in inducing autoreactivity and autoim- 
munity. Together, these results lend further support t o  
the proposed relationship of LFA-1 overexpression, T 
cell autoreactivity, and lupus, and suggest a mechanism 
by which Pca and Hyd may cause lupus in patients 
receiving these drugs. The  results also provide an expla- 
nation as to why Napa does not induce lupus, and 
indicate that the hydrazine side chain of Hyd can 
increase the potency of the parent Phth molecule in this 
system. 
MATERIALS AND METHODS 
Mice. Six-week-old female AKR and New Zealand 
black X New Zealand white (NZB X NZW) mice were 
purchased from Jackson Laboratory (Bar Harbor, ME). These 
mice were housed in a pathogen-free environment maintained 
by the Unit for Laboratory Animal Medicine at the University 
of Michigan (Ann Arbor, MI). 
T cell lines. The conalbumin-reactive, cloned murine T 
helper 2 line, D10.G4.1 (derived from A K R  mice), was pur- 
chased from American Type Culture Collection (ATCC, Rock- 
ville, MD) and maintained as previously described (3,4,7). D10 
cells were subcloned by limiting dilution and a nonautoreactive 
subclone selected for use in these studies. The cells were 
restimulated every 7-8 days with conalbumin (100 pgjml; 
Sigma, St. Louis, MO) and with irradiated (3,000R) AKR 
splenocytes, as previously described (3,4,7). The cells were 
used in proliferation assays or for flow cytometric analysis at 
least 7 days after restimulation. Where indicated, the cells were 
treated for 6 days with Pca (Sigma), Napa (Sigma), Hyd 
(Sigma), Phth (Aldritch, Milwaukee, WI), or HU (Sigma), 
beginning 24 hours after restimulation. 
T cell proliferation assays. T cell proliferative re- 
sponses were measured as previously described (3,4,7). Briefly, 
2 X lo4 D10 cells were cultured in round-bottom 96- 
well microtiter plates with 2 X lo4 irradiated (3,000R) 
thioglycolate-induced AKR peritoneal macrophages, with or 
without 100 pgjml conalbumin. T cell proliferation was deter- 
mined 4 days later by 3H-thymidine incorporation. Results are 
the mean +- SEM of quadruplicate determinations, and are 
presented as stimulation indices (SI) in counts per minute, 
calculated as follows: 
T cells cultured with macrophages 
T cells cultured alone + macrophages cultured alone SI = 
Flow cytometric analysis. D10 cells were reacted with 
anti-murine CD1 l a  (purified from the supernatant of the 
M17/4.2 hybridoma cell line [13], obtained from ATCC), 
washed 3 times, then reacted with fluorescein isothiocyanate 
(F1TC)-conjugated goat anti-mouse Ig (Cappel Laboratories, 
West Chester, PA), as previously described (3,4,7). The stained 
cells were analyzed using a Coulter ELITE flow cytometer. 
Quantitation of T cell DNA methylation. T cell DNA 
was isolated and hydrolyzed to nucleosides with DNAse 1, 
phosphodiesterase, and alkaline phosphatase, using previously 
published protocols (1,2). Total genomic deoxycytosine (dC) 
and deoxymethylcytosine (d"C) content in the hydrolysate was 
determined by reverse-phase high-performance liquid chroma- 
tography (HPLC), as previously described (1,2). Results are 
presented as a percentage of the total d"C content, calculated 
as % d"C = (dmC/[dmC + dC]) x 100. 
Adoptive transfers. Female AKR mice received 5 X 
10' untreated or drug-treated D10 cells via the tail vein every 
2 weeks for a total of 6 injections, using 5 mice per group. The 
mice were killed for serologic and histologic analysis 4 weeks 
after the last injection. 
Autoantibody enzyme-linked immunosorbent assays 
(ELISAs). Anti-double-stranded DNA (dsDNA) and anti- 
single-stranded DNA (ssDNA) ELISAs were performed on 
mouse sera using previously published protocols (7). Purified 
ssDNA was obtained from Sigma, while dsDNA consisted of 
cesium chloride-purified KS + - SV2CAT plasmid. Pooled 
sera from 6-month-old female NZB X NZW mice were used as 
positive controls. 
Histologic analysis. Hematoxylin and eosin staining on 
sections of the kidney, liver, lung, brain, heart, spleen, thymus, 
skin, and intestine from the experimental mice was performed 
using published protocols (3,4,7). Immunofluorescent staining 
of the kidney tissues using FITC-conjugated goat anti-mouse 
IgG (Sigma) was performed as previously described (3,4,7). 
RESULTS 
Drug effects on T cell autoreactivity. Initial ex- 
periments compared the study drugs for their ability to  
induce autoreactivity. DZO cells were used, because they 
had been previously shown to  become autoreactive 
following treatment with Pca and 5-azaC (4). The D10 
cells were treated with 0-50 pA4 Pca, Napa, Hyd, or 
Phth, or 10 pM HU. Ten pM HU is the highest 
concentration tolerated by cloned T cells, and is suffi- 
cient to modify expression of some genes (e.g., CD4) 
(14). After a t  least 2 cell cycles (6 days) in the presence 
of these drugs, the cells were washed and the prolifera- 
tive response to syngeneic macrophages was measured. 
Figures 1A and B show that Pca, Napa, Hyd, and Phth 
all increased the proliferative response to  macrophages 
without antigen. Pca was more effective than Napa, 
as reported previously (2), and Hyd was more potent 
than Phth. Treatment with HU produced no significant 
autoreactive response (mean SI 1.1), as observed previ- 
ously (14). 
Drug effects on T cell LFA-1 expression. D10 
cells were then treated for 6 days with 10 p M  HU, 50 
Pca or Napa, or 10 pA4 Hyd or Phth, and examined for 
LFA-1 expression by flow cytometry. These concentra- 
tions were chosen because they are close t o  the thera- 
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Figure 1. Autoreactivity in drug-treated D10 cells that were treated with the indicated concentrations of the test drugs, and, 
6 days later, cultured with equal numbers of irradiated syngeneic peritoneal macrophages. Proliferation was measured 4 days 
later by 'H-thymidine incorporation. A, Procainamide (Pca)- versus N-acetylprocainamide (Napa)-treated cells ( P  < 0.005). 
B, Hydralazine (Hyd)- versus phthalazine (Phth)-treated cells (P  < 0,001). Bars show the mean i- SEM of quadruplicate 
determinations in 3 representative, independent experiments. For reference, T cells cultured alone gave an average background 
response of 2,034 t 230 counts per minute (mean 2 SEM), and the average autoreactive response for cells treated with the 
5 0 - f l  concentrations for all 4 drugs was 6,270 2 779 cpm. 
peutic concentrations of Pca (10-30 pA4) and Hyd 
(0.5-5.0 ph f )  (1,2), and because autoreactivity was de- 
tected at these concentrations. The results are shown in 
Figures 2A-F. Untreated (control) cells expressed rela- 
tively low levels of LFA-1, as did HU-treated cells. Pca 
induced a subset that overexpressed LFA-1, as previ- 
ously described (7). This subset was smaller in Napa- 
treated cells. Nearly all Hyd-treated cells overexpressed 
LFA-1, and Phth induced LFA-1 overexpression on a 
smaller subset. These results correlate with the degree of 
autoreactivity seen. However, it should be noted that in 
both the autoreactivity assays and the LFA-1 expression 
studies, greater variability was seen in the serial repeat 
experiments with the Hyd- and Phth-treated cells than in 
the cells treated with the other 3 drugs. This was also 
seen in human T cells treated with these drugs (1,2), and 
may be due to the delayed effect that Hyd has on DNA 
methylation (1). 
Drug effects on T cell DNA methylation. D10 
cells were treated with the same concentrations of the 
test drugs as in Figure 2, and, 6 days later, DNA was 
isolated and hydrolyzed to nucleosides with DNAse, 
phosphodiesterase, and alkaline phosphatase, and total 
dC and d"C content was measured by reverse-phase 
HPLC. We found that d"C represented 3.3% of the 
total dC content in untreated D10 cells. Pca caused a 
5.5% decrease, and Hyd a 3.6% decrease, in total d"C 
content. The other drugs were relatively less potent, with 
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Phth causing a 2.4% decrease, and Napa a 1.8% de- 
crease. In contrast, HU increased total d"C content by 
9.7%, as reported by others (12) (mean of 5 independent 
experiments for each test drug, with each determination 
performed in duplicate; P < 0.05, Pca versus HU). 
Overall, this trend is similar to that seen previously with 
these drugs in human (Jurkat) T cells (2), although the 
decreases were quantitatively smaller in our study. 
Autoantibody responses induced by drug-treated 
T cells. Using 5 animals for each drug-treated line, 5 X 
lo6 D10 cells were then treated with the same concen- 
trations of each drug as above, and injected intrave- 
nously into syngeneic recipients. Controls included un- 
treated D10 cells. The mice received a total of 6 
injections spaced 2 weeks apart, and were killed 4 weeks 
later. Sera were diluted 1 : l O O  and antibodies to ssDNA 
and dsDNA were measured by ELISA. Figure 3A shows 
the anti-ssDNA antibody response in the 5 groups of 
mice, using NZB X NZW mice as a positive control. 
Overall, cells treated with Pca and Hyd gave the highest 
anti-ssDNA response, and HU and Napa, the lowest. 
The Phth-induced response was slightly less than that 
seen with Hyd and Pca. This distribution was highly 
significant overall ( P  = 0.0001 by analysis of variance 
[ANOVA]). An IgG-specific ELISA gave similar results 
(mean 5 SEM optical density [OD] units Pca 0.327 t 
0.042, Napa 0.071 2 0.018, Hyd 0.326 ? 0.129, Phth 
0.194 t 0.050, and HU 0.094 2 0.014). Figure 3B shows 
the same groups analyzed for anti-dsDNA antibodies. 
Again, Pca and Hyd gave the greatest results, and HU, 
Napa, and Phth, the lowest. Untreated D10 cells gave 
no significant anti-ssDNA or anti-dsDNA responses 
(0.180 t 0.080 and 0.080 2 0.035 OD units, respective- 
ly). By ANOVA, the distribution was again significant 






Figure 3. Anti-DNA antibodies in sera from mice receiving drug-treated D10 cells. Female AKR mice were given 6 intravenous 
injections of D10 cells treated with the test drugs. Four weeks after the last injection, the mice were killed. Sera were diluted 1 : l O O  
and tested for A, anti-single-stranded DNA (anti-ssDNA) or B, anti-double-stranded DNA (anti-dsDNA) antibodies by enzyme- 
linked immunosorbent assay. Pooled sera from New Zealand black X New Zealand white (NZB/W) mice were included as a positive 
control. Each point represents the mean of quadruplicate determinations on sera from a single mouse. Bars show the mean ? SEM 
for each group. O.D. = optical density units; Hu = hydroxyurea; see Figure 1 for other definitions. 
(P = 0.0042). Using Tukey's Studentized Range and 
Bonferroni t-tests, the response induced by Pca, Hyd, 
and Phth was significantly (P < 0.05) greater than that 
by Napa and HU. 
Histologic changes induced by drug-treated T 
cells. Similar to the results seen in the other assays, only 
0.5 t 0.2; P < 0.001). Mice receiving HU-treated cells 
developed minimal changes (0.2 f 0.1). 
DISCUSSION 
These experiments were designed to further test 
mice receiving Pca- or Hyd-treated D10 cells developed 
significant proliferative glomerulonephritis, pulmonary 
alveolitis, or periductal lymphocytic infiltration in the 
liver. The histologic changes induced by Pca have been 
previously shown (4). Figures 4A, C, and E show the 
liver, lung, and renal disease induced by Hyd-treated 
cells and observed in 5 of 5 mice receiving these cells. 
Figures 4B, D, and F show representative sections from 
mice receiving Phth-treated cells, and appear normal. 
The liver, lung, and kidney in mice receiving HU- and 
Napa-treated cells also appeared normal (not shown). 
Using an arbitrary 0-4+ scale to quantitate the degree 
of histologic change in the kidneys, livers, and lungs, and 
combining the scores of all 3 organs for each mouse, 
mice receiving Pca-treated cells developed significantly 
more total tissue damage than did mice receiving Napa- 
treated cells (mean f SEM 2.1 f 0.2 versus 0.5 2 0.2; 
P < 0.001 by Student's t-test), and mice receiving 
Hyd-treated cells developed greater tissue damage than 
did mice receiving Phth-treated cells (1.8 5 0.3 versus 
the proposed relationship between T cell LFA-1 over- 
expression, autoreactivity, and autoimmunity, using 2 
drugs known to cause drug-induced lupus and analogs 
known or proposed to be less potent. The effects of Pca 
were compared with Napa, which is known to be less 
potent in causing lupus (8,9), and those of Hyd were 
compared with Phth to test the proposed role of the 
hydrazine side chain in inducing autoimmunity. HU was 
included to control for possible effects due to DNA 
synthesis inhibition, and to evaluate the effect of a drug 
that increases DNA methylation (11,12). We have pre- 
viously compared these drugs in human T cell clones, 
and found that Pca, Napa, Hyd, and Phth can inhibit 
DNA methylation and induce autoreactivity. However, 
Pca was -100-fold more potent than Napa in inducing 
autoreactivity, while Hyd and Phth were comparable in 
effect (2). 
The system used in the present study was one 
previously described by our group, in which murine 
CD4+ T cells are treated with DNA methylation inhib- 
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Figure 4. Histologic analysis of the liver, lung, and kidney from mice 
receiving drug-treated D10 cells. Liver, lung, and kidney samples from 
representative mice were fixed, sectioned, and stained with hematoxy- 
lin and eosin, then analyzed by light microscopy. A, Liver section from 
a mouse receiving hydralazine (Hyd)-treated cells, showing a mono- 
nuclear periductal infiltrate with destruction of the bile duct (original 
magnification X 60). B, Liver section from a mouse receiving phthala- 
zine (Phth)-treated cells. The histologic structure appears normal 
(original magnification X 60). C, Lung section from a mouse receiving 
Hyd-treated cells, showing an interstitial pneumonitis with septa1 
widening due to infiltration by inflammatory cells (original magnifica- 
tion X 60). D, Lung from a mouse receiving Phth-treated cells, with 
normal architecture. E, Glomerulus from a mouse receiving Hyd- 
treated cells, showing hypercellularity and increased mesangial matrix 
(original magnification X 120). F, Normal glomerulus from a mouse 
receiving Phth-treated cells (original magnification X 120). 
itors, then given in adoptive transfer to syngeneic female 
recipients. Inhibiting T cell DNA methylation causes an 
increase in LFA-1 expression, making the cells respon- 
sive to normally subthreshold stimuli, including self class 
I1 major histocompatibility complex molecules without 
appropriate antigen (6,7). The recipients develop an 
autoimmune disease resembling murine chronic graft- 
versus-host disease, with an immune complex glomeru- 
lonephritis, pulmonary alveolitis, liver lesions resem- 
bling primary biliary cirrhosis, and IgG antibodies to 
ssDNA and dsDNA (3,4,7). Both chronic graft-versus- 
host disease and the D10 model appear to use a similar 
mechanism (7). It is recognized that humans with drug- 
induced lupus rarely develop many of these manifesta- 
tions (15). However, the clinical manifestations seen in 
murine chronic graft-versus-host disease are strain- 
dependent (16). It is possible that differences between 
the present murine model and human drug-induced 
lupus also reflect basic genetic differences between mice 
and men. 
The present study confirmed that Pca is more 
potent than Napa in inducing T cell autoreactivity. This 
suggests that the aromatic amine on the Pca molecule is 
necessary for inducing autoreactivity. Hyd was also more 
potent than Phth in this system. The difference between 
Hyd and Phth potency in this and the previous report (2) 
could be due to differences in the T cells used, or to 
species-specific differences in the response to these 
drugs. It is worth noting that the kinetics of DNA 
hypomethylation induced by Pca and Hyd are different. 
While Pca is a competitive inhibitor of DNA MTase (17) 
and causes a rapid decrease in total T cell d"C content 
(l), the effects of Hyd are delayed (1). This led us to 
propose that a metabolite of Hyd may be responsible for 
the DNA hypomethylation and subsequent effects on 
the cell (1). The variability in the potency of Hyd and 
Phth thus may reflect differences in the metabolism of 
these drugs to active compounds. In both the human and 
murine systems, it is apparent that Phth is capable of 
inducing some degree of autoreactivity, confirming that 
the hydrazine side chain is not required for this effect. In 
addition, some of the mice receiving Phth-treated cells 
also developed autoantibodies. However, the hydrazine 
side chain does appear to increase potency in the present 
system. 
The present studies also compared the effects of 
these drugs on T cell LFA-1 expression. A positive 
correlation was observed between LFA-1 overexpression 
and T cell autoreactivity. This is not unexpected, since 
inducing LFA-1 overexpression by transfection also in- 
duces autoreactivity (6,7). 
The 5% decrease in d"C content induced by Pca 
was less than the 14% previously reported using Jurkat 
cells (1,2). The reason for this is unclear, but may reflect 
a species-specific difference in the sensitivity of T cells to 
DNA methylation inhibitors, since Pca also caused an 
identical 5% decrease in murine EL-4 cells (3). Others 
have noted species and even strain-specific differences 
in overall levels of DNA methylation (18-20), support- 
ing this interpretation. The decrease corresponds to the 
demethylation of -110,000 cytosine residues (21). Since 
relatively few methylated cystosines in regulatory se- 
quences can suppress gene expression (22), a change of 
this magnitude could be significant. 
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The ability of D10 cells treated with these drugs 
to induce autoimmunity followed the same trends that 
were seen with LFA-1 overexpression and autoreactiv- 
ity. Again, Pca and Hyd induced the highest autoanti- 
body titers and the greatest amount of tissue damage. 
The use of 6 adoptive transfers minimizes interexperi- 
mental variability, so the results observed probably 
represent a valid approximation of the relative potency 
of these drugs. The correlation of the degree of autore- 
activity with disease severity argues that the autoreac- 
tivity observed in vitro also occurs in vivo, resulting in 
autoimmunity. We have previously pointed out the 
similarities between the present system and chronic 
graft-versus-host disease, another model in which T cells 
responding to Ia molecules in vivo produce a similar 
lupus-like disease (16,23). The similarities between these 
systems argue that similar mechanisms are causing the 
autoimmunity. Alternatively, others have proposed that 
hypomethylated DNA may contribute to a lupus-like 
disease by directly activating B cells (19). We have 
reported that D10 cells made autoreactive by LFA-1 
transfection cause a similar disease without DNA hy- 
pomethylation (7), thus arguing against this interpreta- 
tion. Furthermore, heat-killed hypomethylated cells do 
not induce autoimmunity, further arguing against this as 
the primary mechanism. However, the hypomethylated 
DNA could potentially contribute to disease severity by 
augmenting autoantibody responses. 
Together, these results support the proposed 
relationship between LFA-1 overexpression, T cell au- 
toreactivity, and autoimmunity. They also suggest a 
reason why Napa does not induce autoimmunity, and 
indicate that the hydrazine side chain on Hyd can 
increase potency of the parent molecule in this system. 
Together with the findings of earlier work, these results 
indicate a mechanism by which Pca and Hyd could cause 
autoimmunity in humans, and which could contribute to 
the development of idiopathic human lupus. We have 
already reported that T cells from patients with idio- 
pathic lupus have hypomethylated DNA, as well as an 
autoreactive subset that overexpresses LFA-1 (5,25). 
Similar studies in patients receiving Pca and Hyd would 
help determine whether this mechanism also contributes 
to drug-induced lupus. It should be noted that drug- 
induced lupus caused by Pca and Hyd have certain key 
differences, including the specificity of the autoantibod- 
ies made and in the incidence of arthritis and serositis 
(15), although there is considerable overlap in both 
clinical and serologic manifestations (26). The reasons 
for this are uncertain, but could reflect effects of other 
metabolites of these drugs, or differences in the interac- 
tions of these drugs with DNA, modifying antigenicity as 
proposed by others (27-29). Nonetheless, this system 
indicates a mechanism by which these drugs can be 
shown to cause a lupus-like autoimmune disease. Other 
agents or events increasing LFA-1 expression and induc- 
ing autoreactivity by inhibiting DNA methylation or 
other mechanisms could cause a similar lupus-like 
disease. 
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